Cabometyx (Cabozantinib) – Solid Tumors | HongKong DengYue Medicine

Cabometyx Cabozantinib Application Scope

• Advanced Renal Cell Carcinoma (RCC): Monotherapy for patients previously treated with VEGF inhibitors; first-line treatment in combination with nivolumab.

• Hepatocellular Carcinoma (HCC): For patients previously treated with sorafenib.

• Differentiated Thyroid Cancer (DTC): For adults and pediatric patients aged 12 and older with locally advanced or metastatic disease that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible.

• Neuroendocrine Tumors (NETs): For adults and pediatric patients aged 12 and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic or extra-pancreatic neuroendocrine tumors.

  

Cabometyx Cabozantinib Characteristics

• Ingredients: Cabozantinib

• Properties:​ Tyrosine kinase inhibitor

• Packaging Specification:​ Bottles containing 30 tablets (20 mg, 40 mg, or 60 mg)

• Storage:​ Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F)

• Expiry Date: As stated on the packaging

• Executive Standard: ​Manufactured in compliance with Good Manufacturing Practice (GMP) standards

• Approval Number: U.S. FDA NDA 208692; EU/1/13/890/004

• Date of Revision: Please refer to the latest official prescribing information for the most current revision date

• Manufacturer: Ipsen Pharma

Guidelines for the Use of Cabozantinib Cabozantinib

• Dosage and Administration:

  • Recommended Dose:

    • Monotherapy: 60 mg orally once daily.

    • Combination with Nivolumab: 40 mg orally once daily with nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks.

  • Administration:

    • Take orally, with or without food.

    • Swallow tablets or capsules whole; do not chew or crush.

  • Missed Dose:​

    • If a dose is missed, take it as soon as remembered on the same day.

    • If the next dose is due within 12 hours, skip the missed dose; do not take two doses at the same time.

• Adverse Reactions:

  • Common Adverse Reactions:

    • Fatigue

    • Diarrhea

    • Decreased appetite

    • Nausea

    • Weight loss

  • Serious Adverse Reactions:

    • Hepatotoxicity

    • Hypertension

    • Palmar-plantar erythrodysesthesia

    • Gastrointestinal perforations and fistulas

    • Hemorrhage

    ​

• Contraindications:

  • Hypersensitivity to cabozantinib or any component of the formulation.

  • Severe hemorrhage or risk of severe hemorrhage.

• Precautions:

  • Monitor liver function tests regularly.

  • Monitor blood pressure; manage hypertension appropriately.

  • Assess for signs and symptoms of gastrointestinal perforation and fistulas.

  • Evaluate for signs of hemorrhage.

  • Withhold or dose reduce as necessary for adverse reactions.

Cabozantinib Interactions

• Strong CYP3A4 Inhibitors: Avoid concomitant use; may increase cabozantinib plasma concentrations.

• Strong CYP3A4 Inducers: Avoid concomitant use; may decrease cabozantinib plasma concentrations.

• Other Medications: Consult healthcare provider for potential drug-drug interactions.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.